Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic and Oncological Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KAP1/TRIM28 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KAP1/TRIM28 Recombinant Protein (PHD-Bromodomain / Full Length) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for biochemical screening. |
View KAP1 Products |
| Gene Delivery | KAP1/TRIM28 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression validation. |
View KAP1 Products |
| Benchmark Ab | Anti-KAP1/TRIM28 Benchmark Antibody Recombinant positive control for Western Blot, IHC, and IP assays. |
View KAP1 Products |
| Validator | KAP1/TRIM28 siRNA Set For target knockdown verification and specificity assays. |
View KAP1 Products |
| Related Target A | SETDB1 Histone methyltransferase that physically interacts with KAP1 to mediate gene silencing. |
View SETDB1 Products |
| Related Target B | MDM2 E3 ligase cooperating with KAP1 in p53 inactivation and degradation pathways. |
View MDM2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PHD-Bromodomain Small Molecule Screening | High-purity, structurally intact recombinant KAP1 PHD-Bromodomain proteins with verified theoretical MW. |
| Subfamily Off-target Profiling | Homolog panel screening support with sequence-verified TRIM family proteins. |
| Lack of Controls | Clinical-grade benchmark antibodies included in the portfolio. |
| False Positives in Knockdown | Sequence-specific siRNA pool for target-specific validation. |
Live KAP1/TRIM28 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KAP1/TRIM28 therapeutics is intensifying, with major players shifting focus from traditional gene silencing to small-molecule epigenetic readers and targeted protein degradation (PROTACs). As first-generation therapies reach preclinical validation, the next wave of R&D is targeting the specific protein-protein interaction (PPI) domains of KAP1 to overcome drug resistance in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Preclinical Biotech, Academic Consortia | Breast Cancer, Melanoma | Target Degradation Assay (Need Lentivirus for reporter cell lines) |
| Small Molecule (PHD-Brimodomain) | Epigenetics-focused Pharma | Ovarian Cancer, Glioblastoma | Affinity/Binding Assays (Need high-purity recombinant domains) |
| Combination Therapy | Oncology Therapeutics Developers | Immunotherapy-resistant Tumors | Synergy Validation (Need SETDB1/MDM2 co-assays) |